Business Context and Reporting Period
This Form 6-K was filed by NLS Pharmaceutics Ltd., not Newcelx Ltd. It covers December 2021 and was signed on December 15, 2021. The filing reports an amendment dated December 14, 2021, to the company’s Standby Equity Distribution Agreement with YA II PN, Ltd. (“YA”).
Key Financial Metrics
- The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating financial metrics.
- The amended facility permits the company to request an advance of up to the lesser of 100% of the average daily trading value of its common shares during the preceding five trading days or $4.0 million.
Material Changes
The amendment increases or clarifies the maximum advance amount available under the September 27, 2021 SEDA. It also permits the company to specify a minimum acceptable price for share sales instead of using the standard advance price under the SEDA.
Guidance, Risks, and Unusual Items
- The minimum acceptable price may not exceed 85% of the volume-weighted average price on the last completed trading day before delivery of an advance notice.
- The arrangement may provide financing through sales of common shares and therefore may result in equity dilution. The filing does not state whether any advances or share sales had occurred as of the filing date.
- The filing provides only a summary of the amendment; the complete terms are contained in Exhibit 99.1, Amendment No. 1 to the SEDA.
- No management guidance, operating outlook, contingencies, or other unusual items are disclosed.
Investor Verification Checklist
- Confirm that the filing issuer is NLS Pharmaceutics Ltd. rather than Newcelx Ltd.
- Review Exhibit 99.1 for the complete SEDA amendment terms, including pricing, share issuance, termination, and other conditions.
- Verify whether the company subsequently drew on the facility and the number of shares issued or issuable to YA.
- Assess potential dilution and the company’s liquidity needs in light of the $4.0 million maximum advance provision.